What We Do | MAAP

What Is MAAP?

The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) is a multi-organization and multi-national consortium led by ASLM, and funded by the UK Government’s Fleming Fund that focuses on the response to the global threat of antimicrobial resistance (AMR), with the goal of improving laboratory capacity and diagnosis, as well as data and surveillance of AMR through a ‘One Health’ approach.

MAAP seeks to establish a system for the collection, storage, and analysis of AMR and antimicrobial use (AMU) data across Africa. MAAP ensures that data are analysed with national and and provide actionable information in support of controlling AMR and developing policies at institutional, national and regional levels. MAAP links up with the QWArS project, which further consolidate country capacity to analyse AMR data, and the EQuAFRICA project, which addresses gaps in the quality of AMR laboratory testing.

Take a look at MAAP’s Project Brief here, loaded with invaluable information about the state of AMR in Africa, recommendations for the medical laboratory community, and how MAAP is helping address the problem.                                                                                   

Fleming Fund UKaid
African Union Africa CDC ASLM One Health Trust ECSA InSTEDD CEDEAO ECOWAS IQVIA

What Are MAAP's Objectives?

AMR poses a critical global health threat to populations around the world. Every year, AMR kills millions of people and places a massive burden on local, national, and international health systems. In coordination with 14 priority African countries the MAAP consortium works to:

  • Collect and analyse AMR and AMU data to better understand the AMR burden
  • Inform public health and policy interventions with the end goal of reducing the global AMR burden, improving access to antibiotics, and strengthening national health and laboratory systems
  • Increase the volume of ‘analysable data’ by collecting data in sites previously not contributing to the surveillance systems, by digitizing paper-based information and by ranking the quality of the data to improve their inference
  • Propose simple data formatting solutions to facilitate reporting to GLASS and WHONET systems
  • Share the results at country and regional level to drive the evidence-based development of national and regional AMR and AMU surveillance systems that can support swift public health action

MAAP In the First Two Years MAAP Has:

  • Engaged 14 countries in West, East, Central, and Southern Africa from selected sites, and collected information on the capacity of 393 laboratories conducting clinical bacteriology testing
  • Collected and digitized AMR and antimicrobial consumption (AMC) data for the years 2016, 2017 and 2018
  • Reviewed 819,584 AMR records, spanning from 2016-2019, from 205 laboratories across the participating countries. Read the reports here
  • Released a policy brief with infographic aid to help unpack and distil the data collected and analysed to date
  • Built in-country capacity to use WHONET
AMR Country Report
14 Country Reports of AMR data collected between 2016-2019

MAAP's Anticipated Outcomes

  • Improved baseline spatio-temporal mapping of AMR and AMU data by increasing the volume of ‘analyzable’ data
  • Identification of areas for improvement at national and site level in support of sustainable and representative surveillance systems for AMR and AMU
  • Improved policies and guidelines for AMR control and prevention for the Africa continent in line with the Africa CDC AMRSNET
  • Increased local capacity for AMR and AMU data collection and analysis

Project Team

Edwin Shumba
Project Lead
Email